31 results
6-K
CNTB
Connect Biopharma Holdings Ltd
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) and a reduction of ³2 points from baseline at Week 16; and change from … ; the key secondary endpoints were the proportion of patients with Investigator Global Assessment (IGA) score 0 or 1 and a reduction of2 points at Week 16
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
, including the proportion of patients achieving an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) and a reduction of ³2 points … for each CBP-201 group compared with the placebo group; the key secondary endpoints were the proportion of patients with an Investigator Global Assessment
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
5 Jun 23
Current report (foreign)
4:28pm
involvement; EASI=eczema area and severity Index; IGA=investigator global assessment; LOCF=last observation carried forward; LS=least squares; Q2W=every 2 … -90=at least 50%, 75%, and 90% decreases from baseline; IGA=investigator’s global assessment; LD= loading dose.; PP-NRS=peak pruritus numeric rating
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
5 Jan 22
Current report (foreign)
5:24pm
39.5 ± 19.5 BMI, body mass index. EASI, Eczema Area and Severity Index. IGA, Investigator Global Assessment. PP-NRS, Peak Pruritus Numerical Rating … and Severity Index score percentage improvement. FAS, full analysis set. IGA, Investigator’s Global Assessment. NRI, non-responder imputation. Q2W
6-K
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
to an open label Q2W rademikibart arm (n=86).
An efficacy analysis in patients that achieved Investigator’s Global Assessment scale (“IGA”) 0/1 or Eczema
6-K
a3ca6
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
c21 epx93
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
raavav u4ydzfz
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.1
sx6k6jr ito2y5
5 Jan 22
Current report (foreign)
5:24pm
F-1
EX-10.10
uvqb2
26 Feb 21
Registration statement (foreign)
4:56pm
DRS
EX-10.7
10b6uvromnmdjozrwpz7
17 Dec 20
Draft registration statement
12:00am
6-K
EX-99.1
zngv18rh
23 Jun 23
House Lease Contract
4:31pm
6-K
EX-99.2
tsk6t sy54gs2ibjeu6m
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
20-F
EX-4.12
mzm gbsnzj3kywkuzi
31 Mar 22
Annual report (foreign)
4:33pm
F-1/A
EX-10.3
91bypvq
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-1/A
EX-10.3
u78ji6mbuk
17 Mar 21
Registration statement (foreign) (amended)
6:38am
DRS/A
EX-10.5
5fhkxbv1w2v
26 Jan 21
Draft registration statement (amended)
12:00am
F-1
EX-10.5
658j86vqq70ougig6ene
26 Feb 21
Registration statement (foreign)
4:56pm